Co-led ProLynx's $70M Series A for ultra-long-acting obesity medicines.
Prolynx is a biotechnology company dedicated to developing ultra-long-acting medicines for obesity and other metabolic diseases
Prolynx is a biotechnology company dedicated to developing ultra-long-acting medicines for obesity and other metabolic diseases. The Company is advancing a proprietary portfolio of extended-duration therapeutic candidates, targeting once monthly and once-quarterly dosing, optimized to smooth the peaks and troughs that can contribute to tolerability issues, and to support more consistent, long-term treatment.